Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof.
Abstract: The present invention provides a novel fusion protein of Flt3L and albumin and its use to increase the Flt3L half-life in vivo and to deliver Flt3L to immune cells in a subject to enhance alternative dendritic cell populations. Use of the fusion protein in combination with other chemotherapeutic, radiotherapeutic and immunotherapeutic methods are also provided.
Type:
Grant
Filed:
January 10, 2019
Date of Patent:
February 15, 2022
Assignee:
The Johns Hopkins University
Inventors:
T. C. Wu, Chien-Fu Hung, Brandon Krishna Lam
Abstract: Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes IL-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes IL12 p40 subunit or a functional fragment thereof, are disclosed. The nucleic acid molecules and compositions further comprising a nucleic acid sequence that encodes an immunogen are also disclosed. Method of modulating immune response and methods of inducing an immune response against an immunogen are disclosed. Therapeutic and prophylactic vaccination methods are also disclosed.
Type:
Grant
Filed:
May 9, 2018
Date of Patent:
February 8, 2022
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
David Weiner, Matthew P. Morrow, Jian Yan
Abstract: Disclosed herein are methods for selectively treating pruritus in a subject having chronic prurigo (CP), including prurigo nodularis (PN), pharmaceutical compositions for use in the treatment of pruritus in a subject having CP or PN, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of pruritus in a subject having CP or PN.
Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
January 11, 2022
Assignees:
AMGEN INC., MEDIMMUNE, LLC
Inventors:
Robert W. Georgantas, III, Chris Morehouse, Brandon Higgs, Koustubh Ranade, Katie Streicher, William Rees, Meina Liang, Raffaella Faggioni, Jing Li, Inna Vainshtein, Yen-Wah Lee, Jingjing Chen, Robert A. Gasser, Jr.
Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.
Type:
Grant
Filed:
January 22, 2021
Date of Patent:
January 11, 2022
Assignee:
Cartesian Therapeutics, Inc.
Inventors:
Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
Abstract: The present invention provides methods for decreasing a nasal polyp score in a subject. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
Type:
Grant
Filed:
July 18, 2018
Date of Patent:
January 4, 2022
Assignees:
SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
Inventors:
Leda Mannent, Gianluca Pirozzi, Brian Swanson, Allen Radin, Namita A. Gandhi, Robert Evans, Jennifer Hamilton
Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.
Type:
Grant
Filed:
January 29, 2021
Date of Patent:
December 14, 2021
Assignees:
NantCell, Inc., Altor BioScience, LLC.
Inventors:
Hing C. Wong, Warren Marcus, Bai Liu, Wenxin Xu, Robert G. Newman, Karen Kage, Lijing You, Peter Rhode, Patrick Soon-Shiong
Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.
Type:
Grant
Filed:
August 14, 2020
Date of Patent:
December 14, 2021
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Marc Chevrier, Kamyar Farahi, Newman Yeilding
Abstract: Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.
Type:
Grant
Filed:
February 4, 2020
Date of Patent:
December 7, 2021
Assignee:
Indiana Research and Technology Corporation
Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
Type:
Grant
Filed:
June 18, 2019
Date of Patent:
November 16, 2021
Assignee:
Altor Bioscience, LLC.
Inventors:
Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
Abstract: The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.
Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant, a cytokine receptor or cytokine ligand, and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.
Type:
Grant
Filed:
March 26, 2019
Date of Patent:
November 9, 2021
Assignee:
Altor Bioscience, LLC
Inventors:
Qiongzhen Li, Xiaoyun Zhu, Hing C. Wong
Abstract: The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.
Type:
Grant
Filed:
March 11, 2019
Date of Patent:
November 2, 2021
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Ray Camphausen, John O'Loughlin, Bernice Yeung, Yihong Zhang
Abstract: The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-PD-1 antibody agent to treat a disorder or disease that is responsive to PD-1 inhibition, such as cancer or an infectious disease.
Type:
Grant
Filed:
November 1, 2017
Date of Patent:
October 26, 2021
Assignees:
ANAPTYSBIO, INC., Tesaro, Inc.
Inventors:
David J. King, Marilyn Kehry, Baochuan Huang
Abstract: A group of peptides is provided which activate or inhibit toll-like receptor 4 (TLR4) and may be used to modulate inflammatory signaling and host defense pathways. The peptides were derived in silico and tested in vitro in cell cultures. These peptides may be used in the preparation of immunomodulatory compositions such as vaccine adjuvants and in pharmaceutical compositions for immunomodulation of the innate immune system such as vaccine adjuvants. The peptides may also be used in the preparation of TLR4 activators, TLR4 inhibitors and MD2 labels, e.g., for research purposes.
Type:
Grant
Filed:
February 16, 2017
Date of Patent:
October 26, 2021
Assignee:
PEPTICOM LTD.
Inventors:
Amit Michaeli, Immanuel Lerner, Anke Burger-Kentischer, Steffen Rupp
Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
Type:
Grant
Filed:
January 17, 2014
Date of Patent:
October 26, 2021
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
Type:
Grant
Filed:
January 10, 2019
Date of Patent:
October 19, 2021
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Ray Camphausen, David Fabrizio, Martin C. Wright, Patrick Gage, John Mendlein
Abstract: The present disclosure relates to suppression of cellular transformation and dysplasia by topical application of Lefty. In particular, the present disclosure provides compositions and methods for topically applying Lefty to treat and prevent cancers.
Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.
Type:
Grant
Filed:
April 28, 2017
Date of Patent:
October 12, 2021
Assignee:
AVEO PHARMACEUTICALS, INC.
Inventors:
Heidi Okamura, William M. Winston, Jr., Laura Poling, Alisa C. Bell